Literature DB >> 12359500

Hypocretins/orexins as integrators of physiological information: lessons from mutant animals.

Luis de Lecea1, J Gregor Sutcliffe, Véronique Fabre.   

Abstract

The hypocretins/orexins (hcrts) are two recently described neuropeptides derived from the same precursor and expressed in a few thousand neurons in the perifornical area of the lateral hypothalamus, which project throughout the brain. The hypocretins bind to two G-protein coupled receptors with different selective affinities. Positional cloning of the gene responsible for a canine model of narcolepsy revealed that this disease is caused by mutations in hypocretin receptor type 2. Parallel studies with hypocretin/orexin knockout mice showed behavioral arrests reminiscent of narcolepsy-like attacks. Narcoleptic patients have decreased hypocretin-containing neurons suggesting that narcolepsy in humans is caused by selective neurodegeneration of hypocretinergic neurons. Additional functions for the hypocretins on regulation of energy balance neuroendocrine release and sympathetic outflow have been described. Here we review studies in humans and mutant animals that have provided clues about the functions of the hypocretinergic system, which appear to involve the coherent regulation of networks that dictate the states of arousal.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12359500     DOI: 10.1054/npep.2002.0892

Source DB:  PubMed          Journal:  Neuropeptides        ISSN: 0143-4179            Impact factor:   3.286


  18 in total

1.  Nicotine self-administration in the rat: effects of hypocretin antagonists and changes in hypocretin mRNA.

Authors:  Mark G LeSage; Jennifer L Perry; Catherine M Kotz; David Shelley; William A Corrigall
Journal:  Psychopharmacology (Berl)       Date:  2010-02-24       Impact factor: 4.530

Review 2.  Orexin/hypocretin modulation of the basal forebrain cholinergic system: Role in attention.

Authors:  J Fadel; J A Burk
Journal:  Brain Res       Date:  2009-08-21       Impact factor: 3.252

3.  Interactions between estrogen effects and hunger effects in ovariectomized female mice. I. Measures of arousal.

Authors:  Deborah N Shelley; Evarose Dwyer; Carolyn Johnson; Knut M Wittkowski; Donald W Pfaff
Journal:  Horm Behav       Date:  2007-07-26       Impact factor: 3.587

4.  Promotion of Wakefulness and Energy Expenditure by Orexin-A in the Ventrolateral Preoptic Area.

Authors:  Vijayakumar Mavanji; Claudio E Perez-Leighton; Catherine M Kotz; Charles J Billington; Sairam Parthasarathy; Christopher M Sinton; Jennifer A Teske
Journal:  Sleep       Date:  2015-09-01       Impact factor: 5.849

Review 5.  Food for thought: the role of appetitive peptides in age-related cognitive decline.

Authors:  Jim R Fadel; Corinne G Jolivalt; Lawrence P Reagan
Journal:  Ageing Res Rev       Date:  2013-02-13       Impact factor: 10.895

6.  Upregulation of orexin/hypocretin expression in aged rats: Effects on feeding latency and neurotransmission in the insular cortex.

Authors:  Janel M Hagar; Victoria A Macht; Steven P Wilson; James R Fadel
Journal:  Neuroscience       Date:  2017-03-24       Impact factor: 3.590

7.  Aging-related deficits in orexin/hypocretin modulation of the septohippocampal cholinergic system.

Authors:  Emily M Stanley; Jim Fadel
Journal:  Synapse       Date:  2012-02-15       Impact factor: 2.562

8.  Distribution of hypothalamic neurons with orexin (hypocretin) or melanin concentrating hormone (MCH) immunoreactivity and multisynaptic connections with diaphragm motoneurons.

Authors:  Varun M Badami; Cory D Rice; James H Lois; Jayesh Madrecha; Bill J Yates
Journal:  Brain Res       Date:  2010-02-06       Impact factor: 3.252

Review 9.  Orexin: pathways to obesity resistance?

Authors:  Tammy A Butterick; Charles J Billington; Catherine M Kotz; Joshua P Nixon
Journal:  Rev Endocr Metab Disord       Date:  2013-12       Impact factor: 6.514

10.  Age-related loss of orexin/hypocretin neurons.

Authors:  B A Kessler; E M Stanley; D Frederick-Duus; J Fadel
Journal:  Neuroscience       Date:  2011-01-22       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.